Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 386, Issue 10002, 2015, Pages 1457-1464

  Zeng, Ming ^b   Mao, Xu Hu ^c   Li, Jing Xin ^a   Tong, Wen De ^d   Wang, Bin ^b   Zhang, Yi Ju ^a   Guo, Gang ^c   Zhao, Zhi Jing ^b   Li, Liang ^a   Wu, De Lin ^e   Lu, Dong Shui ^c   Tan, Zhong Ming ^a   Liang, Hao Yu ^b   Wu, Chao ^c   Li, Da Han ^e   Luo, Ping ^c   Zeng, Hao ^c   Zhang, Wei Jun ^c   Zhang, Jin Yu ^c   Guo, Bo Tao ^c   Zhu, Feng Cai ^a   Zou, Quan Ming ^c   more..

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Kangwei Biological Technology   (China)

^e Ganyu Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN A; PLACEBO; RECOMBINANT HELICOBACTER PYLORI VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; BACTERIAL VACCINE; RECOMBINANT PROTEIN;

ADOLESCENT; ANTIBODY TITER; ARTICLE; BLOATING; CHILD; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HUMAN; IMMUNOGENICITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STOMACH PAIN; VACCINATION; VOMITING; ACTIVE IMMUNIZATION; AGE; CLINICAL TRIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; SEX DIFFERENCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; BACTERIAL VACCINES; CHILD; DOUBLE-BLIND METHOD; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, ACTIVE; MALE; RECOMBINANT PROTEINS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84944165411     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60310-5     Document Type: Article

References (30)

1. JR Warren, B Marshall Unidentified curved bacilli on gastric epithelium in active chronic gastritis Lancet 1 1983 1273 1275
2. LM Brown Helicobacter pylori: epidemiology and routes of transmission Epidemiol Rev 22 2000 283 297
3. J Parsonnet, GD Friedman, DP Vandersteen et al. Helicobacter pylori infection and the risk of gastric carcinoma N Engl J Med 325 1991 1127 1131
4. JC Atherton The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases Annu Rev Pathol 1 2006 63 96
5. DR Cave How is Helicobacter pylori transmitted? Gastroenterology 113 6 suppl 1997 S9 14
6. The Team of Collaboration of Helicobacter pylori research in China Prevalence of Helicobacter pylori infection in China Mod Digest Interven 15 2010 265 270 (in Chinese).
7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994 IARC Monogr Eval Carcinog Risks Hum 61 1994 1 241
8. F Megraud A humble bacterium sweeps this year's Nobel Prize Cell 123 2005 975 976
9. J Parsonnet Clinician-discoverers - Marshall, Warren, and H pylori N Engl J Med 353 2005 2421 2423
10. G Del Giudice, P Malfertheiner, R Rappuoli Development of vaccines against Helicobacter pylori Expert Rev Vaccines 8 2009 1037 1049
11. NR Salama, ML Hartung, A Muller Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori Nat Rev Microbiol 11 2013 385 399
12. B Corthesy, S Boris, P Isler, C Grangette, A Mercenier Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis J Infect Dis 192 2005 1441 1449
13. P Malfertheiner, V Schultze, B Rosenkranz et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study Gastroenterology 135 2008 787 795
14. P Malfertheiner, F Megraud, CA O'Morain et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report Gut 61 2012 646 664
15. Chinese Medical Association Digestive Disease Branch Helicobacter pylori Consensus Report (2003, Anhui Tongcheng) Mod Digest Interven 9 2004 59 60 (in Chinese).
16. PN Barrett, G Berezuk, S Fritsch et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 377 2011 751 759
17. KL Kotloff, MB Sztein, SS Wasserman, GA Losonsky, SC DiLorenzo, RI Walker Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection Infect Immun 69 2001 3581 3590
18. MD DiPetrillo, T Tibbetts, H Kleanthous, KP Killeen, EL Hohmann Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers Vaccine 18 1999 449 459
19. H Angelakopoulos, EL Hohmann Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers Infect Immun 68 2000 2135 2141
20. T Aebischer, D Bumann, HJ Epple et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines Gut 57 2008 1065 1072
21. S Sougioultzis, CK Lee, M Alsahli et al. Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori Vaccine 21 2002 194 201
22. S Banerjee, A Medina-Fatimi, R Nichols et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers Gut 51 2002 634 640
23. P Michetti, C Kreiss, KL Kotloff et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults Gastroenterology 116 1999 804 812
24. TK Sixma, SE Pronk, KH Kalk et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli Nature 351 1991 371 377
25. 125I-labeled rLTB-UreB in M ice administered with the drug by oral Route Chin J Biologicals 16 2003 215 217 (in Chinese).
26. VP da Hora, FR Conceicao, OA Dellagostin, DL Doolan Non-toxic derivatives of LT as potent adjuvants Vaccine 29 2011 1538 1544
27. CA Garhart, JG Nedrud, FP Heinzel, NE Sigmund, SJ Czinn Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4 Infect Immun 71 2003 3628 3633
28. TH Ermak, PJ Giannasca, R Nichols et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses J Exp Med 188 1998 2277 2288
29. SA Plotkin Immunologic correlates of protection induced by vaccination Pediatr Infect Dis J 20 2001 63 75
30. Y Leal-Herrera, J Torres, G Perez-Perez et al. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico Am J Trop Med Hyg 60 1999 587 592